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The spleen is the main filter for blood-borne pathogens and antigens, as well as a key organ for iron meta-
bolism and erythrocyte homeostasis. Also, immune and hematopoietic functions have been recently unveiled
for the mouse spleen, suggesting additional roles for this secondary lymphoid organ. Here we discuss the
integration of the spleen in the regulation of immune responses locally and in the whole body and present
the relevance of findings for our understanding of inflammatory and degenerative diseases and their treat-
ments. We consider whether equivalent activities in humans are known, as well as initial therapeutic attempts
to target the spleen for modulating innate and adaptive immunity.Introduction
The spleen is organized in regions called the red pulp and white
pulp, which are separated by an interface called the marginal
zone (MZ) (MacNeal, 1929). Blood circulation in the spleen is
open: afferent arterial blood ends in sinusoids at the MZ that sur-
rounds the white pulp. Blood flows through sinusoid spaces and
red pulp into venous sinuses, which collect into efferent splenic
veins. The splenic red pulp serves mostly to filter blood and
recycle iron from aging red blood cells. The structural organiza-
tion and multicellular composition of the organ also permits
monitoring of most of the blood in the red pulp and MZ
(Figure 1A). Diverse splenic populations not only trap and re-
move blood-borne antigens but also initiate innate and adaptive
immune responses against pathogens. The white pulp is struc-
turally similar to a lymph node, contains T cell and B cell zones
(the latter are also called follicles), and allows generation of anti-
gen-specific immune responses that protect the body against
blood-borne bacterial, viral, and fungal infections. Additionally,
the spleen is a site where immune responses that are deleterious
to the host can be regulated.
Leukocytes in the spleen include various subsets of T and
B cells, dendritic cells (DCs), and macrophages that exert
discrete functions (Figure 1B). For example, red pulp macro-
phages are specialized to phagocytose aging red blood cells
and regulate iron recycling and release, whereas MZ macro-
phages and metallophilic macrophages express a unique set
of pattern-recognition receptors and remove at least certain
types of blood-borne bacteria and viruses in the MZ. Beside
specialized macrophages, the MZ also contains MZ B cells
and DCs, which take up passing antigens and migrate to the
white pulp to promote antigen presentation to lymphocytes.
Access to the white pulp is largely restricted to B cells, CD4+
and CD8+ T cells, and DCs (Mebius and Kraal, 2005). Exit of leu-
kocytes from the spleen occurs mostly through the splenic veins
in the red pulp, although some cells in the white pulp can exit the
organ locally via a network of efferent lymphatic vessels (Pellas
andWeiss, 1990). Control of immune cell migration and function-
ality by several types of splenic stromal cells is reviewed else-
where (Mueller and Germain, 2009).806 Immunity 39, November 14, 2013 ª2013 Elsevier Inc.In this review, we examine spleen functions and mechanisms
of actions at the cellular and molecular levels, which are thought
to regulate innate and adaptive immunity, control antigen toler-
ance, and either protect the host or contribute to diseases. To
do so, we first address our current knowledge on the origins,
behavioral activities, and dynamics of different splenic immune
cell populations that: (1) exist in the spleen prior to immune acti-
vation, (2) are recruited in response to a diseased state, (3) are
produced and/or further amplified locally, and (4) are mobilized
from the spleen to other tissues. We then discuss splenic regu-
lation of antigen tolerance, compare hematopoietic activities in
mouse and human spleens, and report initial attempts to target
the spleen for therapeutic purposes.
Resident Lymphocytes
Circulating T and B cells frequently gain access to secondary
lymphoid organs in search for their cognate antigens. Trafficking
and positioning of lymphocytes within defined splenic micro-
environments enables scanning of antigen-presenting cells
(APCs) and is guided by stromal cell networks (Mueller and Ger-
main, 2009), integrins (Lu and Cyster, 2002), chemokines (Ngo
et al., 1999), and other factors (Hannedouche et al., 2011).
For instance, distinct chemokines attract and maintain B and
T cells to their respective zones: Whereas chemokines such as
CXCL13 attract B cells expressing the chemokine receptor
CXCR5 to follicular B cell zones (Ansel et al., 2000), CCL19
and CCL21 attract CCR7+ T cells and antigen-presenting DCs
in T cell zones (Gunn et al., 1999). Intravital lymph node imaging
studies indicate that CCR7 ligand interactions not only guide
T cell homing but also stimulate basal T cell motility inside the
lymphoid organs (Worbs et al., 2007). Both processes facilitate
T cell-DC interactions and thus antigen screening by T cells.
The spleen contains distinct B cell lineages, including follicular
and MZ B cells. Whereas follicular B cells recirculate and partic-
ipate mainly in T cell-dependent immune responses (Tarlinton
and Good-Jacobson, 2013), MZ B cells reside between the
MZ and red pulp, capture antigens carried in the blood via
complement receptors, and promote both T cell-independent
and dependent immune responses (Pillai and Cariappa, 2009).
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Figure 1. Origins, Behavioral Activities, and Functions of Splenic Immune Cell Subsets
(A) Schematic view of spleen’s anatomy.
(B) The cartoon depicts the location of several innate and adaptive immune cell components that are found in the resting spleen and can be involved in disease.
The orange boxes identify the cells’ origins or themechanisms that control their positioning ormotility within the spleen. Thewhite boxes identify generic functions
attributed to the splenic immune cell subsets. Abbreviations are as follows: Ag, antigen; CDP, common DC progenitor; CR2, cannabinoid receptor 2; DC,
dendritic cell; FDC, follicular DC; FO B cell, follicular B cell; GRK2, guanine nucleotide-binding protein-coupled receptor kinase-2; LTb, lymphotoxin b; LXR, liver
X receptor; MZ, marginal zone; RA, retinoic acid; RBC, red blood cell; S1PR1, sphingosine-1 phosphate-1 receptor. See also the Immunology image resource
(http://www.cell.com/immunity/image_resource-spleen), which provides a collection of images of the spleen and its cellular constituents.
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CXCR5 and thus can be expected to respond to follicular-
attracting activity mediated by its ligand CXCL13. However,
MZ B cells overcome such activity by expressing high amounts
of the sphingosine-1 phosphate-1 (S1PR1) and S1PR3 recep-
tors (Cinamon et al., 2004). Binding of the lysophospholipid
S1P to these receptors triggers a chemotactic response and
promotes MZ B cell accumulation in the MZ and red pulp
where S1P is found in higher concentrations. MZ B cells also
express cannabinoid receptor 2 (CR2), which, together withS1PR1 and S1PR3, maintains these cells in the spleen (Muppidi
et al., 2011).
MZ B cells were initially viewed as a sessile immune subset:
they express high amounts of cell surface proteins, such as in-
tegrins VLA-4 and LFA-1 (Lu and Cyster, 2002), which confer
binding to stromal cells and resistance to local shear forces of
blood flow that would otherwise direct the cells to the circulation.
Nevertheless, intravital microscopy studies indicate that MZ
B cells shuttle continually between the MZ and follicles (Arnon
et al., 2013). The mechanisms that control such oscillatoryImmunity 39, November 14, 2013 ª2013 Elsevier Inc. 807
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from themarginal zone into the follicle) followed by S1PR1 resen-
sitization (for migration back to the marginal zone). S1PR1
desensitization is regulated by guanine nucleotide–binding
protein–coupled receptor kinase-2 (GRK2) (Arnon et al., 2011).
GRK2-mediated modulation of S1PR1 permits MZ B cell entry
into white pulp follicles against the S1P gradient and provides
a mechanism for the ability of these cells to deliver opsonized
antigens from the open blood circulation to the follicles. Subse-
quent antigen presentation to follicular B cells, most notably by
follicular DCs, establishes the humoral immune response.
Intravital microscopy studies have confirmed splenic follicular
B cell recirculation, a process involving S1PR1-dependent cell
transit from follicle to MZ and further removal from the spleen
through the red pulp (Arnon et al., 2013). Unlike MZ B cells, follic-
ular B cells fail to express sufficient amounts of integrins and, for
this reason, presumably cannot adhere to the MZ stroma. These
findings suggest that distinct integrin-dependent adhesion
capabilities of B cell subsets force follicular B cells to recirculate
to distant follicles in search for antigens but enrich the MZ with a
population of B cells that is equipped with specialized antigen-
sensing functions.
The spleen also contains a sizable population of natural killer T
(NKT) cells, which sense lipid antigens and are involved in a
broad range of immune responses by secreting cytokines and
inducing downstream activation of adaptive immune cell types.
Lipid antigen presentation is facilitated by CD1d, which is
expressed at elevated amounts by MZ B cells. Intravital micro-
scopy studies indicate that splenic NKT cells locate mostly in
the MZ and red pulp. These cells respond to lipid antigens spe-
cifically in these regions but only in presence ofMZB cells (Barral
et al., 2012). Presumably, MZ B cells undergo physical interac-
tions with NKT cells to facilitate sensing of blood-borne antigens
and NKT cell stimulation. Activation of both T and NKT cells
likely depends on the positioning of B cell lineages in distinct
splenic compartments. Manipulating B cell compartmentaliza-
tion should also considerably alter antigen presentation and
the outcome of adaptive immune responses.
Resident Phagocytes
The spleen hosts all major types of mononuclear phagocytes,
including macrophages, DCs, and monocytes. These cells are
key protectors of the organism because they identify pathogens
and cellular stress, remove dying cells and foreign material,
regulate tissue homeostasis and inflammatory responses, and
shape adaptive immunity. Additionally, they can contribute to
many diseases, as discussed below. Mononuclear phagocytes
remain actively studied >130 years after their discovery (Metsch-
nikoff, 1884) and recent reports continue to reveal unexpected
findings on their origins and functions in various tissues including
the spleen.
Until recently, tissue-resident macrophages were mostly
viewed as descendants of circulating monocytes; however, ge-
netic and cell-fate mapping studies suggest that in the steady-
state, most macrophages and monocytes represent distinct
phagocyte lineages (Schulz et al., 2012; Hashimoto et al.,
2013; Yona et al., 2013). Whereas circulating monocytes derive
from hematopoietic stem cells (HSCs) and discrete interme-
diary progenitors, which occupy specialized niches of the bone808 Immunity 39, November 14, 2013 ª2013 Elsevier Inc.marrow (Mercier et al., 2012), many tissue-resident macrophage
populations, including lung, liver, brain, peritoneal, bonemarrow,
and red pulp splenic macrophages, are established prior to birth
either from elements present in the yolk-sac (Schulz et al., 2012)
or from embryonic fetal liver precursors (Hoeffel et al., 2012;
Guilliams et al., 2013). Consequently, under steady-state, most
splenic and othermacrophages can be generated independently
of adult HSCs and, by extension, of HSC-derived circulating
monocytes. Such macrophages demonstrate the capacity to
self-maintain throughout adult life (Hashimoto et al., 2013).
Macrophage maintenance is not restricted to the steady-state
but can be preserved after enhanced cell turnover triggered by
exogenous challenges (Jenkins et al., 2011; Robbins et al.,
2013).
As notable exceptions, discrete splenic macrophage popula-
tions were recently proposed to derive from CX3CR1intLy6Chi
monocytes, possibly after their transition to CX3CR1hiLy6Clo
monocytes. These include MZ-resident SIGN-R1+MARCO+
and metallophilic CD169+ macrophages (A-Gonzalez et al.,
2013). The development and maintenance of these cells, but
not of other splenic macrophage populations, depends in part
on liver X receptor a (LXRa) signaling because the spleen
of LXRa-deficient mice selectively lacks MZ macrophages.
Conversely, adoptive transfer of LXRa-sufficient monocytes
into LXR-deficient mice partially restores the MZ macrophage
population (A-Gonzalez et al., 2013). LXRa-dependent accumu-
lation ofMZmacrophages also promotesMZB cell retention and
pathogen clearance, which suggests that LXRa signaling regu-
lates systemic antimicrobial immunity by selectively controlling
the splenic MZ niche. LXRa and LXRb are members of the
nuclear receptor superfamily of transcription factors responsive
to oxysterols, which are oxidized derivatives of cholesterol.
Characterizing the spectrum of effects mediated by oxysterols
and other LXR ligands in the spleen promises to be interesting
because initial studies already indicate that these agents might
(1) control the maintenance of MZ macrophages (A-Gonzalez
et al., 2013) and DCs (Gatto et al., 2013), (2) chemoattract
activated B cells to the outer follicle to promote plasma cell re-
sponses (Hannedouche et al., 2011; Liu et al., 2011), and (3) sup-
press splenic myelopoieisis (Yvan-Charvet et al., 2010; Murphy
et al., 2011).
The reasonwhyMZmacrophagesmight have a distinct mono-
cytic origin remains unclear. Possibly, monocyte precursors
confer unique attributes to these cells. For instance, mono-
cyte-derived macrophages appear better equipped than their
yolk-sac-derived counterparts to trigger and shape immune re-
sponses (Schulz et al., 2012), a feature that might be required
for efficient MZ macrophage activity. Additionally, MZ macro-
phages––like gut macrophages (Hashimoto et al., 2013; Yona
et al., 2013)––might never face a truly resting environment
but instead be repeatedly exposed to exogenous antigens,
which trigger monocyte accumulation and local differentiation
into ‘‘activated’’ macrophages. Endogenous circulating ligands,
such as apoptotic cells, might also promote the tonic mainte-
nance of tolerogenic macrophages, as discussed below.
Another longstanding paradigm states that monocytes are
cells that either circulate freely in blood (CX3CR1intLy6Chi cells)
or patrol blood vessels (CX3CR1hiLy6Clo cells) (Geissmann
et al., 2010) but irreversibly differentiate intoDCsormacrophages
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et al., 2010) or nonlymphoid tissues (Nahrendorf et al., 2007;
Grainger et al., 2013). Departing from this paradigm, bona
fide undifferentiated monocytes, including CX3CR1intLy6Chi
and CX3CR1hiLy6Clo subsets, accumulate in the spleen under
steady-state and outnumber circulating monocytes (Swirski
et al., 2009). Intravital imaging of the spleen (Pittet and Weis-
sleder, 2011) indicates that monocytes assemble in clusters of
20–50 cells in the subcapsular red pulp, near venous sinuses
and collecting veins, along the perimeter of the organ; the cells
closely resemble their blood monocyte counterparts and are
morphologically, phenotypically, and functionally distinct from
splenic macrophages and DCs. How splenic monocytes are
maintained and whether they contribute to the replenishment of
MZ macrophages is unknown; however, inflammatory signals
can mobilize these cells en masse to distant tissues, as dis-
cussed below.
Splenic DCs originate from bone marrow HSCs, specialize in
antigen processing and presentation, and are key initiators and
controllers of adaptive immunity (Merad et al., 2013). Besides
interferon (IFN)-producing plasmacytoid cells, splenic DCs
contain at least two classical subsets: CD8a+CD11b– cells,
present in T cell zones and responsible for the uptake of dying
cells and cross-presentation of antigens to CD8+ T cells, and
CD8a–CD11b+ cells, preferentially found in the red pulp and
MZ, expressing major histocompatibility complex class II glyco-
protein (MHCII)-peptide complexes and presenting antigens to
CD4+ T cells (Dudziak et al., 2007; Sancho et al., 2009). The
mechanisms that define splenic DC phenotypic and functional
heterogeneity implicate several molecular pathways, including
at least lymphotoxin b (LTb), Notch2, retinoic acid (RA), and
chemotactic receptor EBI2 signaling. LTb receptor signaling
acts by generating and maintaining CD8a–CD11b+ DCs (Kaba-
shima et al., 2005) and by promoting MZ B cell homeostasis
(Hozumi et al., 2004). Notch2 receptor signaling more specif-
ically controls differentiation of a subset of splenic CD8a–
CD11b+DCs that express the endothelial cell-selective adhesion
molecule (Esam). EsamhiCD8a–CD11b+ DCs are specialized in
CD4+ T cell priming, whereas their Esamlo counterparts secrete
cytokines and are phenotypically closer to, but distinct from,
monocytes and macrophages (Lewis et al., 2011). The vitamin
A derivative RA is also critical for maintenance of the Esamhi
CD8a–CD11b+ DC subset (Klebanoff et al., 2013). Because
mammals lack the capacity to synthesize vitamin A, malnutrition
or other events that alter RA amounts (e.g., total body irradiation,
which impairs the small intestine where RA is obtained) might
reduce the numbers of splenic CD8a–CD11b+ DCs and limit
CD4+ T cell activity, but these impairments might be restored
with RA infusion. Finally, the chemokine receptor EBI2, which
binds 7a,25-dihydroxycholesterol and other closely related oxy-
sterols, regulates positioning of a subset of splenic MZ DCs ex-
pressing the CD8a–CD4+ phenotype. It is not clear how many of
these cells express Esam but, like Esamhi DCs, they appear
required for full-fledged CD4+ T cell activation and antibody
response induction (Gatto et al., 2013; Yi and Cyster, 2013).
Cells Recruited to the Spleen
The spleen has no afferent lymph vessels and collects its leuko-
cytes directly from blood. Besides circulating immune cells thatcontinuously migrate into and out of the resting spleen, diseases
can recruit additional cells to the organ. For instance, the effects
of Listeria monocytogenes, a Gram+ bacterium that infects the
spleen and liver, involve a sequence of actions that includes
CCR2-dependent mobilization of CX3CR1intLy6Chi monocytes
from the bone marrow to the blood stream, followed by
CX3CR1-dependent accumulation in the spleen MZ and T cell
zones and differentiation into DC-like cells that produce tumor
necrosis factor-a (TNF-a) and inducible nitric oxide synthase
(iNOS or NOS2) (Tip-DCs) (Serbina et al., 2003; Serbina and
Pamer, 2006; Auffray et al., 2009). These events are important
for early control of the infection. Listeria also induces NK cell
recruitment to the spleen, at least in part in a CCR5-dependent
manner; NK cells locally produce IFN-g, which is necessary for
differentiating monocytes into cytokine-producing DCs (Kang
et al., 2008). CX3CR1intLy6Chi monocytes accumulate in the
spleen in response to other infections, but the fate of these
cells might diverge depending on the pathogen’s identity. For
instance, different strains of lymphocytic choriomeningitis virus
(LCMV), which trigger either acute or chronic infections, induce
splenic accumulation of monocytes and neutrophils; however,
only the chronic strain sustains a prolonged accumulation of
these cells, which eventually acquire suppressor functions and
chronically inhibit virus-specific T cell immunity (Norris et al.,
2013). This process also involves inflammatory monocyte-
derived DCs activated by LCMV to phagocytose apoptotic eryth-
rocytes and produce interleukin-10 (IL-10) (Ohyagi et al., 2013).
Additionally, bacterial infection can induce the recruitment of a
unique population of B cells to the spleen (Rauch et al., 2012).
These cells, called innate response activator (IRA) B cells, likely
derive from peritoneal B1a B cells, accumulate mainly in the red
pulp, are retained locally in a VLA-4 and LFA-1-dependent
manner, and are the main producer of granulocyte-macrophage
colony-stimulating factor (GM-CSF). Mice in which GM-CSF
production is only completely deficient in B cells show a severe
IL-1b, IL-6, and TNF-a cytokine storm, impaired bacterial clear-
ance, and decreased mouse survival in response to experi-
mental sepsis, suggesting that IRA-B cells represent important
regulators of innate immune activity. How GM-CSF produced
by IRA-B cells precisely controls splenic innate immune cells re-
mains unexplored.
Cells Amplified or Produced in the Spleen
It is well appreciated that hematopoietic stem and progenitor
cells (HSPCs) exist in bone marrow niches where they produce
their lineage descendants (Weissman et al., 2001). It has also
been established for more than 5 decades that at least a fraction
of bone marrow HSPCs can enter circulation in the steady-state
(Goodman and Hodgson, 1962). Circulating HSPCs, which resist
cell death by upregulating the don’t-eat-me signal CD47 (Jaiswal
et al., 2009), traffic through peripheral tissues and lymph (Mass-
berg et al., 2007) and can re-engraft bonemarrow niches (Wright
et al., 2001). If conditions permit, circulating HSPCs produce
lineage-descendant cells outside the bone marrow (Massberg
et al., 2007). This process, called extramedullary hematopoiesis,
occurs predominantly in the liver in the developing embryo (in this
case, before the inception of medullary hematopoiesis) but also
in adult tissues including the spleen (Figure 2). Indeed, under spe-
cific disease conditions, splenic HSPCs profoundly expand andImmunity 39, November 14, 2013 ª2013 Elsevier Inc. 809
Figure 2. Splenic Myeloid Cell Production
and Mobilization under Inflammatory
Conditions
In the steady-state, circulating HSPCs do not seed
the spleen and can re-engraft the bone marrow.
Several inflammatory conditions including some
cancers, myocardial infarction, and atheroscle-
rosis, however, induce HSPC survival and en-
graftment in the spleen, followed by local
monocytic and granulocytic cell production. Some
of the newly made cells might remain in their
native tissue where they participate in the regula-
tion of immune tolerance (see Figure 3) or relocate
to distant tissues. The orange boxes identify
molecular mechanisms that are known to
orchestrate these sequential processes. Abbrevi-
ations are as follows: AngII, angiotensin II;
CMP, common myeloid progenitor; GM-CSF,
granulocyte-macrophage-colony-stimulating fac-
tor; GMP, granulocyte-macrophage progenitor;
HDAC, histone deacetylase; HSC, hematopoietic
stem cell; IL, interleukin; MDP, macrophage/DC
progenitor; Rb, retinoblastoma; S1PR1, sphingo-
sine-1 phosphate-1 receptor.
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least by GM-CSF, IL-1b, and IL-3 (Marigo et al., 2010; Leuschner
et al., 2012; Robbins et al., 2012; Bayne et al., 2012; Pylayeva-
Gupta et al., 2012; Griseri et al., 2012), depends on the C/EBPb
transcription factor (Marigo et al., 2010), and might be inhibited
by prostaglandin E2 (PGE2) (Young et al., 1988).
Splenic hematopoiesis has been reported in several animal
models of disease including cancer (Bronte et al., 2000; Mar-
igo et al., 2010; Cortez-Retamozo et al., 2012), atherosclerosis810 Immunity 39, November 14, 2013 ª2013 Elsevier Inc.(Murphy et al., 2011; Robbins et al.,
2012; Dutta et al., 2012), myocardial
infarction (Leuschner et al., 2012), and
colitis (Griseri et al., 2012). These
studies suggest that HSPCs originally
described in bone marrow accumulate
in high numbers in the splenic red
pulp of diseased animals and are
more skewed toward myelopoiesis at
the expense of erythropoiesis and lym-
phopoiesis. The myeloid progenitors
proliferate similarly to their bone mar-
row counterparts, form normal colonies
in vitro, and produce their progeny
in vivo.
Whether cells produced in the spleen
differ from those derived from the bone
marrow will require further study. Mono-
cyte- and granulocyte-like cells newly
produced in the spleen might derive
from unique circulating progenitors or
receive microenvironmental education
signals that are specific to the spleen. In
this first scenario, the splenocytes might
become distinct from their bone marrow
counterparts. A second scenario postu-
lates that the splenic niches reproduces
all essential features of bone marrowniches and produce monocytes and neutrophils that are other-
wise comparable to their bone marrow counterparts. Remark-
ably, many recent studies have reported the accumulation of
immature myeloid-derived suppressor cells (MDSCs) in tumor-
bearing animals, most notably in the spleen and also in the
tumor stroma (Gabrilovich et al., 2012). Both MDSCs and granu-
locyte-macrophage progenitor-derived splenic monocytes
and neutrophils are CD11b+Gr-1+ in mice and likely overlap
with each other. MDSCs express immunosuppressive enzymes
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(NOS2), produce reactive oxygen species (ROS), inhibit T cell
proliferation and IFN-g production in coculture experiments,
and suppress antitumor T cell activity in vivo. The full spectrum
of MDSCs’ suppressive functions might not be acquired in the
spleen but upon recruitment to the diseased sites (Haverkamp
et al., 2011). Interestingly, CD11b+Gr-1+ cells accumulating in
the bone marrow of tumor-bearing mice are not immunosup-
pressive (Ugel et al., 2012). It is thus likely that distinct factors
might be delivered to MDSCs at different locations and times
during their ontogenic development.
Cells Mobilized from the Spleen
The spleen, by mobilizing its motile constituents, can establish
connections with other body locations. A prototypical example
would beCD4+ andCD8+ T cell redistribution to nonlymphoid tis-
sues following recognition of cognate antigens in the splenic
white pulp. In addition to lymphocytes, the spleen contributes
mononuclear phagocytes in various disease settings (Figure 2).
For instance, ischemic myocardial injury increases the motility
of reservoir monocytes and induces a massive exit of this popu-
lation to the circulation (Swirski et al., 2009). A fraction of the
deployed splenic monocytes accumulates in the ischemic
myocardiumwhere it contributes to wound healing. Mechanisms
of monocyte release are distinct in bone marrow and spleen:
emigration of bone marrow monocytes depends on CCR2
signaling, whereas emigration of splenic monocytes is controlled
by angiotensin II. This hormone, whose concentration increases
in serum after myocardial infarction, directly contributes to
monocyte expulsion by signaling through the angiotensin
type-1 receptor expressed on the surface of reservoir mono-
cytes (Swirski et al., 2009). Other studies suggest that splenic
monocytes can bemobilized to the ovaries to enhance the ovula-
tory process (Oakley et al., 2010); identification of a causal link
between splenocytes, ovulation, and fertility, and factors that
induce splenocyte mobilization during ovulation, will require
further examination.
In addition to bona-fide reservoir monocytes, CX3CR1int
Ly6Chi monocytic cells newly produced in the spleen (discussed
above) also enter the circulation and relocate to distant tissues.
In the context of cancer, these cells can migrate to the tumor
stroma and contribute new tumor-associated macrophages
(TAMs) throughout cancer progression (Cortez-Retamozo
et al., 2012; Cortez-Retamozo et al., 2013). This activity might
be deleterious to the host because TAMs can stimulate tumor
growth, and their density predicts patient survival in several can-
cer types (Qian and Pollard, 2010; Steidl et al., 2010; DeNardo
et al., 2011). Newly made CX3CR1intLy6Chi splenic monocytes
contribute macrophages in other diseases, including atheroscle-
rosis (Dutta et al., 2012; Robbins et al., 2012) and myocardial
infarction (Leuschner et al., 2012). These findings suggest that
certain diseases elicit macrophage responses by inducing the
recruitment of monocytes both from bone marrow and spleen.
This notion is divergent from reports from the past 50 years,
which indicated that circulating monocytes are bone marrow-
derived cells (van Furth and Cohn, 1968; Geissmann et al.,
2010). To reconcile these findings, we propose that the bone
marrow autonomously maintains monocytes in circulation in
steady-state; under inflammatory conditions, the spleen andperhaps other extramedullary tissues are also amenable to pro-
duce monocyte-like cells and continuously mobilize these cells
in the circulation (Figure 2).
Spleen and Antigen Tolerance
Peripheral tolerance is characterized by systemic immune unre-
sponsiveness to repeatedly applied, or large amounts of, antigen
(high antigen zone tolerance), or to mucosal contact with the
antigen (oral tolerance). Splenectomy can selectively abrogate
high antigen zone tolerance (Buettner et al., 2013), indicating
that splenocytes are involved in this process. Anterior cham-
ber-associated immune deviation (ACAID) is a form of tolerance
that ensues when antigens are placed in the anterior chamber,
vitreous cavity, and in the subretinal space of the eyes (Streilein
andNiederkorn, 1981). Antigen inoculation in these immune priv-
ileged sites elicits a systemic immune response characterized by
the induction of antigen-specific antibodies, failure tomount cell-
mediated immunity, and allograft acceptance (Streilein, 2003).
Splenic macrophages are likely an important component of
this response because both splenectomized and F4/80-deficient
mice do not develop tolerance to antigens injected in the eye (Lin
et al., 2005). Data suggest that intraocular APCs, mostly F4/80+
macrophages, capture antigens in the anterior chamber, cross
the ocular trabecular meshwork, reach the bloodstream, and
home to the MZ of the spleen, where they release chemokines,
such as CXCL2, and attract NKT cells and other cell types
(Faunce and Stein-Streilein, 2002; Masli et al., 2002). Macro-
phages and NKT cells, as well as local MZ B cells and macro-
phages, orchestrate a promiscuous environment that is enriched
in immunosuppressive soluble factors such as thrombospondin,
TGF-b, and IL-10 (Faunce and Stein-Streilein, 2002; Masli et al.,
2002; Sonoda et al., 1999). The process eventually involves con-
version of eye antigen-specific CD4+ and CD8+ T cells into reg-
ulatory (Treg) cells, which are dispensable for early immune
unresponsiveness but essential for maintenance of long-term
tolerance (Getts et al., 2011).
Macrophages, particularly those in the MZ, do not only trap
particulate materials and circulating apoptotic cells but also
regulate tolerance to antigens (Figure 3). For example, deletion
of CD169+ macrophages causes delayed clearance of injected
dying cells in the MZ and abrogates tolerance to an encephalito-
genic peptide delivered by apoptotic cells (Miyake et al., 2007).
Similarly, MZ macrophage depletion by chlodronate liposomes
accelerates systemic tolerance breakdown in mouse models of
systemic lupus erythematosus and promotes immunity toward
apoptotic cell antigens (McGaha et al., 2011). The molecular
events triggering the tolerogenic process in MZ macrophages
remain largely unknown but might involve at least LXR and indo-
leamine 2,3 deoxygenase (IDO) signaling. Apoptotic cell engulf-
ment activates LXRa and LXRb and induces the expression
of the receptor tyrosine kinase Mer, which is required for
phagocytosis (A-Gonzalez et al., 2009). Full Lxr null macro-
phages show a selective defect in phagocytosis of apoptotic
cells that results in aberrant proinflammatory immune activity
(A-Gonzalez et al., 2013). Mice lacking LXRs develop autoanti-
bodies and autoimmune glomerulonephritis, and LXR agonist
treatment ameliorates disease progression in mouse models of
lupus-like autoimmunity (A-Gonzalez et al., 2009). Considering
that LXRs control MZ macrophage homeostasis (A-GonzalezImmunity 39, November 14, 2013 ª2013 Elsevier Inc. 811
Immunity
Reviewet al., 2013), we can speculate that LXR signaling that occurs
during apoptotic cell delivery promotes MZ macrophage self-
renewal and maintenance. Additionally, the immunoregulatory
enzyme IDO1, produced by SignR1+MARCO+MZmacrophages
within 24 hr from the administration of apoptotic cells, promotes
CD4+ T cell-mediated tolerance to apoptotic cell antigens (Rav-
ishankar et al., 2012).
Apoptotic cell clearance by MZ macrophages might also pre-
vent apoptotic material to reach the white pulp and induce proin-
flammatory immune activity (McGaha et al., 2011). For instance,
IDO blockade with the pharmacologic agent D-1-methyl-trypto-
phan reduces TGF-b production but increases TNF-a and IL-12
transcripts in DCs and macrophages, respectively, resulting in
loss of CD4+ T cell-mediated tolerance and induction of a
lupus-like disease (Ravishankar et al., 2012). MZ macrophages
might also regulate the functional activation status of other
APCs that come in contact with the apoptotic material. In partic-
ular, CD8a+ DCs are required for tolerance initiation following
phagocytosis of apoptotic debris through a wide array of recep-
tors, including PSR, b5A integrin, CD36, scavenger receptor BI,
CD14, and CD68 (Iyoda et al., 2002). The population of CD8a+
DCs responsible for apoptotic cell tolerance is constituted by a
limited subset of langerin (CD207)+ DCs that are physically close
to MZ macrophages; these DCs cross-present antigen to CD8+
T cells (Qiu et al., 2009) and can induce suppressive FoxP3+ Treg
cells from the naive T cell population (Yamazaki et al., 2008).
Splenic pDCs are conditioned by soluble factors (like TGF-b)
released from macrophages processing apoptotic material and
contribute to antigen tolerance, e.g., in the context of allogeneic
bone marrow transplantation (Bonnefoy et al., 2011).
Besides sensing apoptotic death, the spleen might regulate
peripheral tolerance by expressing the autoimmune regulator
gene (AIRE). This transcription factor regulates negative selec-
tion of autoreactive T cells in the medulla of the thymus by
inducing ectopic expression of tissue-specific antigens (Mathis
and Benoist, 2009). Splenocytes expressing AIRE and tissue-
specific antigens have been suggested to promote self-toler-
ance (Gardner et al., 2008). Reported AIRE+ splenic cells include
a CD11c+ DC subset (Lindmark et al., 2013) and bone marrow-
derived epithelial cell adhesion molecule (EpCAM)+ CD45lo
APCs (Gardner et al., 2013). The latter cells might mediate toler-
ance by inactivating autoreactive T cells and without involving
Treg cells. This mechanism of tolerance induction might be
important for controlling autoreactive T cells that escape thymic
selection.
Antigen tolerance might also be triggered in the spleen by
tumor-derived signals. In line with this notion, splenectomy
before or early after tumor implantation can retard tumor growth
in colon carcinoma, mammary carcinoma, and melanoma-
bearing mice (Fotiadis et al., 1999; Schwarz and Hiserodt,
1990). The paradoxical, beneficial effect of splenectomy may
be viewed in light of the recent findings indicating that the spleen
produces myeloid cells that are recruited to the tumor stroma
(Cortez-Retamozo et al., 2012; Cortez-Retamozo et al., 2013),
but also because the spleen locally orchestrates tolerance in-
duction to tumor-antigens (Figure 3). As discussed above, the
spleen of tumor-bearing mice often contains increased numbers
of Ly6Chi monocytic cells (Ugel et al., 2012). These cells share
markers with granulocyte-macrophage progenitors (GMPs),812 Immunity 39, November 14, 2013 ª2013 Elsevier Inc.are enriched in theMZ, andmight produce not only mononuclear
phagocytes but also granulocytes through a tumor-induced
pathway involving transcriptional silencing of the retinoblastoma
gene and epigenetic modification operated by histone deacety-
lase 2 (Ugel et al., 2012; Youn et al., 2013). These cells capture
tumor-derived material and cross-present tumor-associated
antigens to memory CD8+ T cells transiting the spleen MZ; this
process causes T cell unresponsiveness to tumor antigens
(Ugel et al., 2012). Splenic accumulation of Ly6Chi monocytes
depends on the CCR2-CCL2 axis because MZ anatomical alter-
ation, splenomegaly, and tumor-antigen tolerance are absent in
either Ccr2 or Ccl2 genetically ablated mice; moreover, CCL2
serum concentrations in cancer patients correlate with accumu-
lation of myeloid progenitors and predict overall survival of
patients who respond to cancer vaccines (Ugel et al., 2012).
Tumor-derived apoptotic bodies and microvesicles might con-
tribute to this process and involve several cells in the MZ,
including MZ macrophages considering their derivation from
Ly6Chi monocytes (A-Gonzalez et al., 2013).
The mouse spleen also accumulates immunosuppressive
myeloid cells after trauma and sepsis (Makarenkova et al.,
2006; Delano et al., 2007); in particular, ARG1+ myeloid cells
can be detected as early as 6 hr after traumatic stress in T cell
zones around germinal centers (Makarenkova et al., 2006).
Thus, the spleen apparently maintains peripheral tolerance
induced by tissue remodeling in various contexts including
ACAID, tissue injury, and cancer. In particular, the MZ likely
continuously samples blood for the presence of signals delivered
as particulate fractions in the blood, including apoptotic bodies
and microvescicles. Resident elements including specialized
macrophages and DCs assure a steady-state control of autoim-
mune reactivity, further supported by local myelopoiesis during
cancer or intense traumatic or inflammatory stress (Figure 3).
The Spleen in Mice and Humans
Mouse and human spleens are mostly similar anatomically,
although the human MZ is more organized, with clearly identifi-
able outer and inner layers surrounded by a large perifollicular
zone (Mebius and Kraal, 2005). Although a vast array of diseases
such as infections, vascular alterations, autoimmune disorders,
hematologic malignancies, and metabolic syndromes can cause
splenomegaly in mice, this main sign of hyperslenism is not
commonly associated with the development of human solid
tumors. Interestingly, spleen enlargement is commonly seen in
tumor cell transplantable models (Gabrilovich et al., 2012) but
to a lesser extent or not at all in genetically engineered models
of cancers in which, nonetheless, splenic HSPC and myeloid
activity significantly increase (Cortez-Retamozo et al., 2012;
Cortez-Retamozo et al., 2013). So splenomegaly and extrame-
dullary hematopoiesis are not necessarily connected.
On the other hand, several examples of increased presence
and activity of splenic HSPCs in human pathology suggest that
the embryonic role of the spleen in blood formation can be
conserved in adult life. Splenic hematopoiesis is observed in
osteopetrosis (Freedman and Saunders, 1981) and in metastatic
carcinomas of different origins, including lung, breast, prostate,
and kidney cancers (O’Keane et al., 1989). These findings
were recently confirmed and extended. Splenic GMP-like cells
are found in elevated numbers in patients with invasive lung
Figure 3. The Spleen Is a Site of Immune Tolerance Induction
The spleen’s tolerogenic role depends on MZ cellular interactions between different macrophage subsets, CD8+ DCs, pDCs, inflammatory Ly6Chi monocytes,
NKT cells, TNF-related apoptosis inducing ligand (TRAIL)+ CD8+ T cells and CD4+Foxp3+ Tregs. Orange boxes show molecules involved with tolerance
regulation. These include cytokines and soluble molecules (thrombospondin, TGFb, IL-10), membrane-boundmolecules (TRAIL and programmed death ligand 1
[PD-L1]), enzymes (IDO, ARG, NOS, and 12/15 lipoxigenase [12/15 LO]) and reactive oxygen species (ROS). These circuits operate: (1) in steady-state by sensing
apoptotic remnants released by privileged tissues such as the eye (ACAID) or during normal cell turn-over in conventional tissues, and (2) under inflammatory
conditions such as trauma, acute, and chronic inflammation including cancer, which result in increased loads of apoptotic materials andmicrovesicles, as well as
stimulation of splenic myelopoiesis (see Figure 2).
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in vitro and following in vivo engraftment in immunodeficient
mice (Cortez-Retamozo et al., 2012). When scale differences
between the species are taken into account, the precursors’quantity in humans andmice bearing cancer is similar. Moreover,
HSPCs’ presence in patients shortly after heart attack supports
the notion that the spleen acts as a reservoir and source of
monocyte progenitors (Dutta et al., 2012; Leuschner et al.,Immunity 39, November 14, 2013 ª2013 Elsevier Inc. 813
Immunity
Review2012). Additionally, transformed human myeloid cells can select
the spleen for their survival. The spleen of myelofibrosis patients
contains more malignant CD34+ HSPCs than bone marrow and
blood; these cells support a prolonged myeloid and lymphoid
reconstitution and retain a differentiation program similar to
that of normal HSPCs (Wang et al., 2012). Activatedmyeloid cells
are also found in higher proportions in the spleen’s MZ of
patients after trauma or severe sepsis (Cuenca et al., 2011).
Splenectomy predisposes patients to death from ischemic
heart disease and increases the risk to develop sepsis and
meningitis in response to Streptococcus pneumoniae, Neisseria
meningitidis, and Hemophilus influenza type B infections (Amlot
and Hayes, 1985; Ram et al., 2010; Robinette and Fraumeni,
1977). Humans with acute Plasmodium falciparum malaria who
had previously undergone splenectomy show decreased clear-
ance of parasitized red blood cells from the circulation (Chotiva-
nich et al., 2002). Splenectomy might also protect against blunt
trauma complications by dampening systemic inflammation
(Crandall et al., 2009). However, the question of whether asplenia
predisposes to either decreased or increased risk of cancer
growth or recurrence has not received clear answers from clin-
ical studies, with most of the data indicating a modest if any
effect on overall risk after splenectomy (Cadili and de Gara,
2008; Robinette and Fraumeni, 1977). Only few studies indicate
an increased incidence of cancer in patients splenectomized
for nontraumatic causes, but treatments for underlying disease
and lifestyle habits, such as cigarette smoking, could not be
ruled out in explaining these increased risks (Mellemkjoer
et al., 1995). On the other hand, studies on concomitant rather
than preceding splenectomy in patients with gastric, colon,
and pancreatic cancers have unveiled a decreased disease-
free and overall survival but suffer from the confounding biases
of more locally advanced tumors, increased operative time,
and blood loss that are usually associated with the clinical indi-
cation of splenectomy (Cadili and de Gara, 2008). In summary,
analysis of clinical outcomes of splenectomy in humans confirms
its relevance in controlling immune responses to bacteria and
parasites, but the impact on cancer progression has not yet
been clarified.
Therapeutic Targeting
Targeting the spleen for therapeutic purposes offers several
advantages. First, the large blood flux through the organ should
facilitate delivery of systemically administered drugs and cells.
Second, splenic reservoir precursors could be intercepted
before they are mobilized and enter pharmacodynamical unfa-
vorable compartments, such as the tumor stroma; these precur-
sors could be uses as ‘‘Trojan horses’’ to deliver drugs or to
shape immune repertoires in the tumor stroma. Third, the
spleen’s anatomical structure is naturally fit to regulate re-
sponses to blood-borne antigens. The main goals pursued in
targeting the spleen are inducing tolerance to ‘‘self’’ peripheral
antigens, restraining monocyte-dependent inflammatory re-
sponses, or controlling tumor-induced myelopoiesis and im-
mune suppression. Below we discuss how targeting the spleen
could serve to manipulate tolerance induction, tumor-induced
myelopoiesis, and immune suppression in therapy.
From the first demonstration, dating >30 years ago, that allo-
geneic splenocytes treatedwith common crosslinking chemicals814 Immunity 39, November 14, 2013 ª2013 Elsevier Inc.induce tolerance to protein antigens administered intravenously
(Miller and Hanson, 1979), several studies in experimental auto-
immune diseases driven by T helper 1 (Th1) and/or Th17 T lym-
phocytes (such as rheumatoid arthritis, type I diabetes, and
multiple sclerosis) have proven that a single intravenous injection
of either syngeneic splenocytes or erytrocytes chemically
coupled with ‘‘self’’ peptides or proteins can induce potent anti-
gen-specific tolerance in vivo. This effect relies on apoptotic cell
and erythrocyte clearance from recipient splenic phagocytes,
IL-10 production, and expansion of antigen-induced Treg cells
(reviewed in (Ravishankar and McGaha, 2013). Even though
the spleen’s contribution remains to be formally assessed, treat-
ment’s efficacy seems promising for patients with multiple
sclerosis: in a first-in-human study, high doses of autologous
peripheral blood mononuclear cells chemically coupled with
seven myelin antigens showed decreased T cell reactivity
against these antigens (Lutterotti et al., 2013). Widespread
clinical use of apoptotic cells might be difficult because it re-
quires large cell numbers and standardized protocols, and
because of the complexity and unknown nature of the antigenic
mixture. For these reasons, recent attempts have focused on
manufacturing artificial mimics of apoptotic cells, endowed
with equivalent ability to trigger in vivo tolerance. Clearance of
apoptotic debris can be substituted by artificially engineer-
ing microparticles of either polystyrene or biodegradable
poly(lactide-co-glycolide) beads with encephalitogenic pep-
tides. This approach induces T cell tolerance in mice with relaps-
ing experimental autoimmune encephalomyelitis. Microparticles
are uptaken by MARCO+SIGN-R1+ MZ macrophages, which
trigger a tolerance circuit involving Treg cell activation (Getts
et al., 2011).
It is often viewed as a potential limitation for drug delivery that
many nanoparticle formulations are retained in the spleen.
However, this limitation might represent an opportunity to
therapeutically target splenocytes. For example, nanoparticles
encapsulating short interfering RNA (siRNA) against CCR2 reach
inflammatory Ly6Chi monocytes in the spleen (and to a lesser
extent the bone marrow) upon intravenous injection and effi-
ciently silence expression of the chemokine receptor. The treat-
ment decreases the number of inflammatory monocytes in
atherosclerotic plaques, reduces the infarct size after coronary
artery occlusion, prolongs survival of allogeneic pancreatic islet
transplantation in diabetic mice, and controls tumor growth
by lowering the numbers of tumor-associated macrophages
(Leuschner et al., 2011).
Another strategy consists in creating a barrier between the
precursors within the splenic niche and their target site. The pep-
tide hormone Angiotensin II (AngII) is crucial to maintain self-
renewing HSCs and macrophage progenitors in the spleen of
tumor-bearing hosts. By binding its receptor, AGTR1A, AngII
interferes with the signaling through S1PR1 necessary for cells
to sense the S1P hematic gradient and migrate to blood from
tissues. Interfering with the AngII pathway, by either adminis-
tering AGTR1A antagonist losartan or blocking its production
through the angiotensin converting enzyme inhibitor enalapril,
allowed to interrupt the continuous flux of tumor myeloid cells
at its source, preventing accumulation of Ly-6Chi monocyte-
derived, tumor-promoting macrophages, reducing the number
of detectable lung tumor nodules, and increasing survival of
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Retamozo et al., 2013). Myocardial infarction and atheroscle-
rosis in humans are also associated with increased AngII activity
(McAlpine andCobbe, 1988; Schieffer et al., 2000); thus blocking
AngII signaling could restrain the amplification of deleterious
macrophages in these diseases as well.
Conventional chemotherapy can also be optimized to alter the
tolerogenic splenic niche. Several chemotherapeutic agents
(gemcitabine, fludarabine, sutent, sorafenib, bortezomib, cyclo-
phosphamide, and 5-flourouracyl), when administered at low
dose in tumor-bearing hosts, assure a prolonged depletion of
splenic Ly6Chi monocytes and restore impaired cytotoxic T
lymphocyte (CTL) functions. In fact, chemotherapy allows the
occupation of the splenic niche by CD8+ T cells that actively
restrain replenishment by Ly6Chi monocytes (Ugel et al., 2012).
These findings provide a rationale to explain the often empirical
and paradoxical observations that chemotherapeutics can be
useful adjuvants for adoptive cell therapy of cancer with anti-
gen-specific CD8+ T cells. Indeed, a single inoculation of 5-fluo-
rouracyl before adoptive transfer of telomerase-specific CD8+ T
lymphocytes was found to prolong overall survival in both
immune competent and deficient tumor-bearing mice; more-
over, reconstitution of 5-fluorouracyl-treated mice with Ly6Chi
but not with Ly6Ghi splenocytes fully abrogates the immune
adjuvant activity of chemotherapy (Ugel et al., 2012). The drug
trabectedin, a DNA binder of marine origin approved for treating
soft-tissue sarcoma ovarian cancer patients, also shows selec-
tive activity on mononuclear phagocytes as a main component
of its antitumor activity. Trabectedin activates caspase-8-
dependent apoptosis, and its selectivity for monocytes is due
to differential expression of signaling and decoy TRAIL receptors
(Germano et al., 2013). It is not clear whether other chemothera-
peutic drugs share a similar mechanism of action, but these
results open the possibility to use chemoimmunomodulation to
halt the pathological consequences of altered myelopoiesis in
cancer. Chemotherapeutics that affect immunosuppressive cir-
cuits and induce immunogenic cell death (Kroemer et al., 2013)
could act synergistically in combination and might further in-
crease antitumor immune responses.
Concluding Remarks
Emerging studies are forcing investigators to reconsider the tem-
poral and spatial distribution of hematopoiesis and immune re-
sponses. Tissue- and lymphoid-related circuits promote innate
and adaptive immune cell positioning and reciprocal interplay
with unexpected specificity and complexity. It appears that
distinct sites have evolved to serve specific purposes but our
perception is still limited. For example, the advantage for the
host to establish distinct sites of monocyte production is not fully
understood. Identifying unique splenic signals that instruct
myeloid cells and their precursors locally, and/or functional dif-
ferences between bone marrow and spleen-derived circulating
myelomonocytic cells, might help to further define whether
inflammatory conditions support locational production of circu-
lating cells with unique functions. Analogously, we need to un-
derstand which environmental factors control positioning and
differentiation of DC populations and other immune cells types
in the spleen. Moreover, targeting receptors and/or their corre-
sponding ligands could modulate immune cell positioning and,by extension, the unfolding of undesired adaptive immune
responses, as initial studies seem to suggest. Finally, it is clear
that more studies are needed on human spleen before dismiss-
ing its importance on the basis of the few epidemiology analyses
evaluating the long-term consequences of splenectomy in
patients, often based on the consultation of national registries
and biases related to the criteria used for the statistics.
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